SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (886)7/11/2007 1:33:23 PM
From: tuck  Respond to of 946
 
Yes, and that's been the development/investment thesis behind Pix all along. They might try for non-inferiority, might try to make safety parameters endpoints . . . we'll see what they come up with pending the meeting.

Cheers, Tuck



To: Ian@SI who wrote (886)7/11/2007 3:22:54 PM
From: Icebrg  Respond to of 946
 
Doxorubicin causes irreversible heart damage, which limits its usefulness. Pixantrone is supposed to do away with this very serious limitation.

There have even been some smaller trials where pixantrone has been used with good results for patients who have already reached their maximum doxorubicin dose.

An approval for pixantrone would open new therapeutic options for the treatment of both NHL and breast cancer.

Erik


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News